Publications by authors named "Y K Banasavadi-Siddegowda"
Background: The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME).
Methods: RNA sequencing (RNA-Seq) was used to identify molecular targets of oHSV resistance.
Article Synopsis
- Glioblastoma is a highly fatal brain tumor with chromosomal alterations affecting oncogenes and tumor suppressors, and research identified 6q27 as a poor prognostic marker.
- Using a combination of CRISPR, transcriptomic data, and mouse models, the study explored Pde10a as a potential tumor suppressor in the 6q27 region and found its suppression leads to aggressive tumor behavior and treatment resistance.
- Pde10a suppression was linked to enhanced PI3K/AKT signaling and a change in tumor cell characteristics, suggesting glioblastoma patients with Pde10a loss may have worse outcomes but might benefit from PI3K inhibitors.
Glioblastoma is the most common malignant primary brain tumor. The outcome is dismal, despite the multimodal therapeutic approach that includes surgical resection, followed by radiation and chemotherapy. The quest for novel therapeutic targets to treat glioblastoma is underway.
View Article and Find Full Text PDFArticle Synopsis
- HERVs are remnants of ancient viruses found in our DNA, making up about 8% of the human genome, with HERV-K (HML-2) being linked to certain cancers, especially malignant gliomas.
- The study highlights the abnormal activation of HML-2 in glioblastomas, where it promotes a cancer stem cell-like behavior associated with worse patient outcomes.
- Researchers found that targeting HML-2 can impair tumor growth and stemness in glioblastoma, suggesting it could be a potential target for new cancer therapies due to its role in treatment resistance.
Damage to intervertebral discs (IVD) can lead to chronic pain and disability, and no current treatments can fully restore their function. Some non-surgical treatments have shown promise; however, these approaches are generally limited by burst release and poor localization of diverse molecules. In this proof-of-concept study, we developed a nanoparticle (NP) delivery system to efficiently deliver high- and low-solubility drug molecules.
View Article and Find Full Text PDF